Switching IMMUNITY ON

Mission

riboxx develops, manufactures and markets unique drugs for immunotherapy of cancer or virus diseases.

Drug products

The drug products developed at riboxx pharmaceuticals act by switching the immune system ON. They activate the so called "innate immune system".

The drug products of riboxx pharmaceuticals belong to the class of Toll-like-Receptor 3 agonists (TLR) and RIG-I-like-Receptor (RLR) agonists. The drug substance is RNA (ribonucleic acid).

riboxx pharmaceuticals has developed four families of TLR3 & RLR agonists for immunotherapy of cancer or immunotherapy of virus diseases.

Immunotherapy of cancer

  • RIBOXXIM® is a TLR3 ligand for ex vivo immunotherapy of cancer, therapeutic vaccination against cancer, and prevention of cancer recurrence.
  • APOXXIM® is a TLR3 ligand for first-line immunotherapy of cancer.
  • RIBOXXON® is a TLR3-bioconjugate for targeted immunotherapy of cancer.

Immunotherapy of virus diseases

  • RIBOXXOL® is a TLR3 ligand for therapeutic vaccination against virus diseases, i.e. Hepatitis B virus.

Purchase our GMP TLR3 ligands

Our GMP TLR3 ligands (RIBOXXIM®, APOXXIM®, RIBOXXON®, RIBOXXOL®)  are available for pharmaceutical companies or public institutions performing Phase I to III clinical trials.

We manufacture our GMP TLR3 ligands in 3 standard scales (1 gr./batch, 5 gr./batch or 10 gr./batch). Higher scales are also feasible on demand.

If you are interested in purchasing our GMP TLR3 ligands, please contact us at business.development@riboxx.com.

Cookies faciliate the providing of our online services. By using our online services, you agree to our use of cookies.